Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)
Status:
Completed
Trial end date:
2019-10-28
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive
placebo in the treatment of the negative symptoms of schizophrenia